DRG Epidemiology's coverage of hypertension comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each country, as well as annualized case counts projected to the national population.
In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.
DRG Epidemiology's hypertension forecast will answer the following questions:
Of all people with hypertension, how many in each country across the world have been formally diagnosed?
Of all people diagnosed with hypertension, how many in each country across the world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hypertension over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts 43 hypertension patient populations, as follows:
Prevalence of Hypertension per 100 Among People Aged 20+ in 2020 and 2040
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Hypertension over the Next 20 Years
Total Prevalence of Hypertension
Total Prevalence of Prehypertension
Studies Included in the Analysis of Hypertension
Studies Excluded from the Analysis of Hypertension
Risk/Protective Factors for Hypertension
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.